Truscreen Group (ASX:TRU), a New Zealand based company, has reported experiencing a significant increase in sales during the first quarter of Fiscal Year 2024.

The company’s product sales have surged, with a reported 100% rise comparing the first quarter of 2024 with the corresponding period in 2023.

Furthermore, the company has reported a recovery of market demand in China, with levels returning to those before the impact of the COVID-19 pandemic.

Truscreen Group is a diagnostic company specializing in the development and distribution of cervical screening technology.